Felty's syndrome: favorable response to granulocyte-macrophage colony-stimulating factor in the acute phase.

Abstract

We report a case of Felty's syndrome in which infectious complications due to severe neutropenia could be overcome by short-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, 7 micrograms/kg/day s.c.). Leukocyte counts rose from 1,050/mm3 at presentation to 4,470/mm3 after 15 days of treatment. A flare-up of arthritis was not noted. Defects in granulocyte function and clinical improvement prior to leukocyte rise suggest that the beneficial effect of GM-CSF is mainly due to an improvement of granulocyte function.

• Authors: U Kaiser, M Klausmann, G Kolb, K H Pflüger, K Havemann
• Journal: Acta haematologica (Acta Haematol) Vol. 87 Issue 4 Pg. 190-4 ( 1992) ISSN: 0001-5792 [Print] Switzerland
• PMID: 1519433 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulins
• Recombinant Proteins
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Acute Disease
• Aged
• Blood Cell Count (drug effects)
• Felty Syndrome (blood, drug therapy, immunology)
• Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use)
• Granulocytes (drug effects)
• Humans
• Immunoglobulins (blood, drug effects)
• Male
• Recombinant Proteins (therapeutic use)